The Netherlands has joined the Irish Republic, Denmark, Norway, Bulgaria, and Iceland in suspending the administration of the AstraZeneca vaccine. The Democratic Republic of Congo and Indonesia have delayed the beginning of the vaccine rollout whereas Italy and Austria have suspended the use of certain batches as a precautionary measure.
The European Union’s medicines regulator is investigating whether the Oxford-AstraZeneca Covid-19 vaccine could be linked to a number of reports of blood clots. While the investigation is ongoing, Denmark, Iceland and Norway have suspended the use of this vaccine. Denmark announced the two week suspension on Thursday and Iceland and
South Africa is giving up its stock of Oxford-AstaZeneca Covid-19 vaccines to the African Union and instead is seeking to vaccinate its population with the single-dose Johnson & Johnson drug. The changes in the Covid-19 vaccination policy come after the AstraZeneca vaccine proved to offer minimal protection against the variant
Germany is currently facing a shortage of Covid-19 vaccines that could last up to ten weeks, according to the country’s health minister Jens Spahn. The pace of Germany’s vaccine rollout has been less than ideal, failing to meet many of its own daily vaccination targets. Mr. Spahn’s commentary on Twitter
The European Union is calling on pharmaceutical company and vaccine producer AstraZeneca to publish their vaccine contract. The move comes amid frustration at the vaccine vendor due to delivery shortfalls. The EU has been dissatisfied with the production delays but is unable to release details of the deal due to
The Oxford University and AstraZeneca vaccine will go through another global trial, according to CEO Pascal Soriot. The program had originally been planning to add a subdivision to its existing US trial, however, has decided to re-enter global testing amid criticism over the data to date. The organization has claimed
AstraZeneca and Oxford University’s COVID-19 vaccine has concluded the Phase III trial with a 90% effectiveness rate, according to interim data from the trials. The trial also discovered that the vaccine was only 70% effective when the data of two different dosing regimens were combined. The organizations concluded that the